Skip to content
Search

Latest Stories

Paul Rees steps down as NPA chief executive

Paul Rees steps down as NPA chief executive
Paul Rees

NPA plans to appoint its next chief executive early in the New Year  

Paul Rees MBE, chief executive of the National Pharmacy Association (NPA), has announced his resignation to take on a new role as interim chief executive and registrar of the Nursing and Midwifery Council (NMC) in the new year.

He will join the NMC on a one-year contract starting January 20, where he will oversee the development of a multi-year programme aimed at transforming the NMC's culture and performance.


This follows an independent culture review conducted by Nazir Afzal OBE, which highlighted issues of racism, discrimination, and bullying within the organisation.

The NPA is engaging a leading recruitment agency to find its next chief executive, with plans to make an appointment early in the New Year.

NPA chair Nick Kaye praised Paul’s contributions over the last year, stating: “I’m enormously grateful to Paul and the brilliant NPA team who are doing so much to raise the profile of community pharmacy, campaign for a better deal and improve our outstanding support to members.

“Our board and senior team are pressing ahead with our very successful campaigning and our work to transform the support and services we give to pharmacies across the country.

“The NPA is stronger than ever and everything the team does is there to support our members and their teams, who work tirelessly to support their communities. We’re excited about how we can build even better support and advocacy for our members in the months to come.”

Paul expressed gratitude for his time at the NPA, saying:  “I’ve totally loved my time working with the brilliant staff and board teams at the National Pharmacy Association.

“Working as a team, we’ve completely modernised the NPA and turned it into a high-profile campaigning organisation fighting for a fair deal for community pharmacy – while continuing to deliver a range of great services for independent community pharmacies.

“Now the foundations of the new, modernised NPA are firmly in place, I know the organisation will continue to grow and thrive.

“The fact that the NPA is now well set on its new course was highlighted by the way our brilliant board team – led by our chair Nick Kaye – was out in force being the voice of community pharmacy on national TV and radio, as well in the national press last week, to highlight the results of our ballot on reducing services.

“The NPA has a very bright future – as the voice of community pharmacy, delivering excellent learning and development, brilliant pharmacy advice and support, and gold standard pharmacy insurance.”

Paul described his decision to leave the NPA as difficult but expressed excitement about helping the NMC develop a positive and inclusive culture

He said: “It will be a real wrench to leave and it’s been a decision I’ve had to wrestle with.  I have been deeply affected by working with the NPA – community pharmacy will always have a special place in my heart, even as I move into another part of the healthcare sector.”

“Despite loving the NPA, the pull of helping the NMC to eliminate racism and bullying from within the organisation, embed a positive and inclusive culture, and improve the quality of patient care through the regulation of, and support for, the UK’s 826,000 nurses, midwives and nursing associates, is just too great.”

He also emphasised the urgency to address the findings of the culture review.

“Ensuring the NMC can respond to the shocking findings of the culture review published in the summer by Nazir Afzal and Rise Associates – which highlighted the challenges at the organisation – is an urgent matter for patients, nursing and midwifery professionals, the staff of the NMC, and the nation at large.

“It is because of the scale of the challenge and the need to move with urgency and at pace, that the NMC has asked me to join the team in mid-January.”

Since joining the NPA in November 2023, Paul has worked with board members and staff to energise the organisation and elevate its impact.

Key achievements include:

  • Driving the high-profile Save Our Pharmacies campaign, which has achieved continuous national media coverage to highlight the chronic underfunding and closure of pharmacies
  • Leading the first ever two days of national protest across the community pharmacy sector on 20 June and 19 September
  • Leading the roll out of the Save Our Pharmacies petition, which has amassed more than 350,000 signatures and was presented to Number 10 Downing Street on 19 September
  • Introducing new face-to-face events for members in England, including Meet the NPA events and masterclasses, to help members transform the way they run their pharmacies
  • Rolling out a values-led approach based on the values of professionalism, authenticity, collaboration, innovation, excellence and respect
  • Increasing membership by 3.5% in organisations to 3,179 entities, and 2.4% in branches to 6,056 contracts.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less